This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutIntroducing Enbrel®Heritage of Enbrel®IndicationsTherapeutic IndicationsRheumatoid ArthritisJuvenile Idiopathic ArthritisPsoriatic ArthritisAxial SpondyloarthritisPsoriasis & Paediatric PsoriasisMechanism of actionMode of ActionHalf-lifeDosingDosingRheumatoid Arthritis, Psoriatic Arthritis & Axial SpondyloarthritisJuvenile Idiopathic ArthritisPsoriasisPaediatric PsoriasisAdministration & StorageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacyRapid EffectivenessSustained EffectivenessEffectiveness With Monotherapy or Combination TherapySafetyTolerability Across IndicationsSummary of Prescribing InformationImmunogenicityImmunogenicity & Clinical ResponseImmunogenicity & Enbrel®Experience & InsightsExperience & InsightManufacturingPatient StoriesRheumatoid ArthritisPatient With an Increased Risk of Serious InfectionsMTX-IR PatientPatient Who Is Considering Starting a FamilyElderly-onset RA PatientYoung Patient Worried About the Lifelong Impact of RAYoung Patient Worried About Treatments That Lose Effectiveness Over TimeJuvenile Idiopathic ArthritisJuvenile PatientPatient Moving From Childhood to AdolescenceAxial SpondyloarthritisAS Patients With Heel EnthesitisAS Patients With Functional LimitationsAdvanced AS PatientsPsoriatic Arthritis & PsoriasisPsO Patient With Severe SymptomsPsO Patients With Cyclical SymptomsPsA Patient With Metabolic SyndromePsA Patient With Multiple Skin & Joint SymptomsSupport & ServicesSupport & ServicesUsing Enbrel®Summary of Prescribing InformationPatient ResourcesEventsMaterialsVideos

Half-life

Although treatment with any EMA-approved TNFi therapy results in the modulation or neutralisation of TNF-induced or TNF-regulated activity/responses, there are differences among agents with respect to the biologic structure, pharmacokinetics and half-life.1

    

TNFi therapies approved for RA1-6

   

A short half-life can result in the rapid elimination from the body.1-6

    

Adapted from Furst DE, et al. 2006; Enbrel SmPC; Humira SmPC; Remicade SmPC; Simponi SmPC; Cimzia SmPC; Atiqi S, et al. 2020.

    

Differences in the biologic structure between TNFi therapies may lead to differences in the immunogenicity.7,||,¶

    

  • Enbrel®  has a half-life of approximately 70 hours and a washout period of just 15 days2,8
     
  • Enbrel® has a relatively shorter half-life compared to other biologics1-6

    

Vishal

A young RA patient worried about treatments that lose effectiveness over time

Meet Vishal

Monica

An RA patient considering starting a family and may need a treatment that can be interrupted

Meet Monica
  *Mean half-life. Range: 7 to 300 hours.2  Mean half-life.3  Median half-life. Range: 8 to 9.5 days.4  §±3 days.5  

||Many factors impact the efficacy and safety of biologics and how an individual patient responds to the biologic. The presence or absence of neutralising ADAbs is one of these factors but does not allow any conclusions about the overall efficacy and safety of a drug. The occurrence of ADAbs is also influenced by several factors, including co-treatment with immunosuppressive drugs such as MTX. As immunogenicity analyses are product specific, comparison of antibody rates with those from other products is not appropriate. ADAbs can be neutralising or non-neutralising and both may impact the bioavailability and safety of the drug. Neutralising antibodies bind to the binding site of the therapeutic protein and neutralise it, whereas non-neutralising antibodies bind to the therapeutic protein but do not neutralise it.7

    

Antibodies to Enbrel® have been detected in the sera of some subjects treated with Enbrel®. These antibodies have all been non-neutralising and are generally transient. There appears to be no correlation between the antibody development and clinical response or AEs.2

    

    

ADAb, anti-drug antibody; AE, adverse event; EMA, European Medicines Agency; F(ab), fragment antigen-binding; MTX, methotrexate; RA, rheumatoid arthritis; SmPC, summary of product characteristics; TNF, tumour necrosis factor; TNFi, tumour necrosis factor inhibitor.

    

References:

Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36(3):159-167.Enbrel. Local product document. Version LPDENB062021.Humira. Summary of product characteristics. Accessed July 18, 2022. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdfRemicade. Summary of product characteristics. Accessed July 18, 2022. https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdfSimponi. Summary of product characteristics. Accessed July 18, 2022. https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdfCimzia. Summary of product characteristics. Accessed July 18, 2022. https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdfAtiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312.NHS. Patient Information Leaflet. Guidelines for rheumatology patients on biologic therapy. Rheumatology Department.

    

Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

    

PP-ENB-IND-0814 August 2022

    

Mechanism of Action
Badge Immunogenicity and clinical response

Detectable ADAbs may reduce the response of TNFi therapy

Learn More Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ENB-IND-0814

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​